|
As a result of the Minnesota Legislature’s 2023 Session, there are several upcoming changes to Minnesota’s Prescription Drug Price Transparency reporting (MN 2023 Session Law Chapter 70, Article 2, Sections 8-21, 43). The changes include:
- Technical fixes to existing reporting—which become effective July 1, 2023, and
- New reporting on Drugs of Significant Public Interest beginning in 2024.
Changes to existing reporting
The Minnesota Department of Health (MDH) is preparing updated reporting requirements under the original Price Transparency legislation. The updated reporting requirements will apply to drugs with price increases and with introductions for sale in the United States beginning July 1, 2023. Because the statute requires manufacturers to report to MDH no later than 60 days after the effective date of a new or increased price, the first reporting deadline under the updated guidance is August 30, 2023.
Consistent with the initial publication of reporting guidance in 2021, MDH will release a draft of the updated reporting guidance for public comment. The draft will be included in a GovDelivery message to subscribers of the Prescription Drug Price Transparency updates, as well as be posted on the Prescription Drug Price Transparency (RxPT) website. Following the release, stakeholders will have two weeks to review and provide feedback to MDH on draft updates to reporting guidance. MDH will review the feedback received and issue final updated guidance on the RxPT website, as well as update the online reporting system.
Upcoming communication on new reporting
MDH is in the initial stages of developing the Drugs of Significant Public Interest reporting initiative, under which drug manufacturers, wholesalers, pharmacy benefit managers, and pharmacists will report data for select drugs beginning in 2024.
As work progresses in 2023, MDH will provide updates on implementation, opportunities for public comment, and resources to support reporting entities newly engaging in this reporting initiative.
Stay connected
Stakeholders interested in receiving announcements on prescription drug price transparency at MDH may subscribe to Prescription Drug Price Transparency updates.
|
